However, two of these monoclonal antibodies, bevacizumab (Avastin®) and FDA approved ranibizumab (Lucentis®), show anti-VEGF properties and may be used to treat age related macular degeneration (AMD) and diabetic retinopathy. Here, VEGFA is linked to age-related macular degeneration.